3-(3-iodopropyl)indole | 141972-27-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(3-iodopropyl)indole
• 英文别名: 3-(3-iodopropyl)-1H-indole
• CAS: 141972-27-2
• 化学式: C₁₁H₁₂IN
• 分子量: 285.127
• InChiKey: PAXSXGYJPKPWJQ-UHFFFAOYSA-N

物化性质

• 沸点：
  376.4±25.0 °C(Predicted)
• 密度：
  1.676±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  3-(3-iodopropyl)indole 在 4-二甲氨基吡啶 、 lithium cyclohexylisopropylamide 作用下， 以 乙腈 为溶剂， 反应 17.67h， 生成 ethyl 2-chloro-5-(indol-3'-yl)pent-2-enoate
  参考文献：
  名称：

  Synthesis of 3,4-bridged indoles by photocyclisation reactions. Part 2. Photocyclisation of halogenoacetyl tryptophol derivatives and α-chloro indol-3-ylalkanoate esters

  摘要：

  Irradiation of the trichloroacetates 2, 4 and 5, derived from the corresponding tryptophols, in methanolic acetonitrile results in photocyclisation to the indole 4-position, and the formation of the pyrrolobenzoxocines 9-11. Attempted photocyclisation of the 'reversed' alpha-chloro esters 15a, 15b and 18 was thwarted by readily occurring elimination of HCl, although the dimethyl compound 15c did cyclise to give the cycloheptaindole 20 upon irradiation in acetonitrile.

  DOI：

  10.1039/p19920000813
• 作为产物：
  描述：

  3-(1H-indol-3-yl)propyl 4-methylbenzenesulfonate 在 sodium iodide 作用下， 以 丙酮 为溶剂， 反应 16.0h， 以100%的产率得到3-(3-iodopropyl)indole
  参考文献：
  名称：

  [EN] D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE
  [FR] ANTAGONISTES D2, PROCÉDÉS DE SYNTHÈSE ET MÉTHODES D'UTILISATION

  摘要：

  提供了D2或D3拮抗剂化合物以及公式I和其药学上可接受的盐或异构体的药物组合物，其中R1、R2和R3如本文所定义。该发明还包括制备该发明化合物的方法以及利用该发明化合物治疗由多巴胺D2或D3受体介导的疾病的方法。

  公开号：

  WO2011160084A1

文献信息

• [EN] D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE<br/>[FR] ANTAGONISTES D2, PROCÉDÉS DE SYNTHÈSE ET MÉTHODES D'UTILISATION
  申请人：ALTOS THERAPEUTICS LLC

  公开号：WO2011160084A1

  公开（公告）日：2011-12-22

  Provided are D2 or D3 antagonist compounds and pharmaceutical compositions of formula I and pharmaceutically acceptable salts thereof, or isomers thereof, wherein R1, R2 and R3 are as defined herein. The invention further comprises methods for making the compounds of the invention and methods for the treatment of conditions mediated by the dopamine D2 or D3 receptor from the compounds of the invention.

  提供了D2或D3拮抗剂化合物以及公式I和其药学上可接受的盐或异构体的药物组合物，其中R1、R2和R3如本文所定义。该发明还包括制备该发明化合物的方法以及利用该发明化合物治疗由多巴胺D2或D3受体介导的疾病的方法。
• 4-Phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives
  申请人：H. Lundbeck A/S

  公开号：US20030027832A1

  公开（公告）日：2003-02-06

  The present invention relates to substituted 4 -phenyl- 1 -piperazinyl derivatives having the formula I 1 wherein W is C, CH or N, and the dotted line emanating from W indicates a bond when W is C and no bond when W is N or CH; R 1 and R 2 are independently selected from hydrogen and halogen, provided at least one of R 1 and R 2 is a halogen atom; R 3 is selected from hydrogen, halogen, C 1-6 alkyl, trifluoromethyl, C 1-6 alkoxy, aryloxy, aralkoxy, hydroxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, nitro and cyano n is 2, 3, 4 or 5; X is CH 2 , O, S, CO, CS, SO or SO 2 ; and Q is a group of formula 2 wherein Z is a chain of 3 to 4 chain members; wherein the chain members are selected from C, CH, CH 2 , CO, N and NH, provided that only one of the chain members may be N or NH, and said chain optionally containing one or two double bonds; hvad med acyl?? R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are independently selected from hydrogen, halogen, C 1-6 alkyl, trifluoromethyl, C 1-6 alkoxy, hydroxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino nitro and cyano; provided that X is not O or S when the group Q is attached via an N atom; and any of its enantiomers and acid addition salts thereof. These compounds have high affinity for D 4 receptors.

  本发明涉及具有式I1的取代4-苯基-1-哌嗪基衍生物，其中W为C、CH或N，从W发出的虚线表示当W为C时为键，当W为N或CH时不为键；R1和R2独立地选择自氢和卤素，只要R1和R2中至少有一个是卤素原子；R3选择自氢、卤素、C1-6烷基、三氟甲基、C1-6烷氧基、芳氧基、芳基氧基、羟基、氨基、C1-6烷基氨基、二(C1-6烷基)氨基、硝基和氰基，n为2、3、4或5；X为CH2、O、S、CO、CS、SO或SO2；Q是式2的一个基团，其中Z是3到4个链成员的链；链成员选择自C、CH、CH2、CO、N和NH，只有一个链成员可以是N或NH，该链可选择性地含有一个或两个双键；acetyl如何？R4、R5、R6、R7、R8、R9和R10独立地选择自氢、卤素、C1-6烷基、三氟甲基、C1-6烷氧基、羟基、氨基、C1-6烷基氨基、二(C1-6烷基)氨基、硝基和氰基；只要通过N原子连接时，X不是O或S；及其任何对映体和酸盐。这些化合物对D4受体具有高亲和力。
• 4-Phenyl-1-piperazinyl, -piperidinyl and-tetrahydropyridyl derivatives
  申请人：Bang-Andersen Benny

  公开号：US20060148815A1

  公开（公告）日：2006-07-06

  The present invention relates to substituted 4-phenyl-1-piperazinyl derivatives having the formula I wherein W is C, CH or N, and the dotted line emanating from W indicates a bond when W is C and no bond when W is N or CH; X is CH 2 , O, S, CO, CS, SO or SO 2 ; and Q is a group of formula wherein Z is a chain of 3 to 4 chain members; wherein the chain members are selected from C, CH, CH 2 , CO, N and NH, provided that only one of the chain members may be N or NH, and said chain optionally containing one or two double bonds; provided that X is not O or S when the group Q is attached via an N atom; and any of its enantiomers and acid addition salts thereof. These compounds have high affinity for D 4 receptors.

  本发明涉及具有以下式子I的取代的4-苯基-1-哌嗪基衍生物： 其中，W为C、CH或N，当W为C时，点线由W发出表示键合，当W为N或CH时，则没有键合；X为CH2、O、S、CO、CS、SO或SO2；Q为以下式子的基团： 其中，Z为3至4个链成员的链，其中链成员从C、CH、CH2、CO、N和NH中选择，只有一个链成员可以是N或NH，并且该链可选择包含一或两个双键；当基团Q通过一个N原子连接时，X不为O或S；以及其任何对映异构体和酸加成盐。这些化合物具有对D4受体的高亲和力。
• D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE
  申请人：Luehr Gary W.

  公开号：US20120010228A1

  公开（公告）日：2012-01-12

  Provided are D 2 or D 3 antagonist compounds and pharmaceutical compositions of formula I and pharmaceutically acceptable salts thereof, or isomers thereof, wherein R 1 , R 2 and R 3 are as defined herein. The invention further comprises methods for making the compounds of the invention and methods for the treatment of conditions mediated by the dopamine D 2 or D 3 receptor from the compounds of the invention.

  提供了D2或D3拮抗剂化合物及其制备方法，以及公式I的制药组合物及其药学上可接受的盐或同分异构体，其中R1、R2和R3如本文所定义。本发明还涉及制备本发明化合物的方法，以及利用本发明化合物治疗由多巴胺D2或D3受体介导的疾病的方法。
• D2 antagonists, methods of synthesis and methods of use
  申请人：Luehr Gary W.

  公开号：US08691836B2

  公开（公告）日：2014-04-08

  Provided are D2 or D3 antagonist compounds and pharmaceutical compositions of formula I and pharmaceutically acceptable salts thereof, or isomers thereof, wherein R1, R2 and R3 are as defined herein. The invention further comprises methods for making the compounds of the invention and methods for the treatment of conditions mediated by the dopamine D2 or D3 receptor from the compounds of the invention.

  本发明提供了公式I及其药物可接受的盐或异构体的D2或D3拮抗剂化合物和制药组合物，其中R1、R2和R3如本文所定义。本发明还包括制备本发明化合物的方法以及利用本发明化合物治疗由多巴胺D2或D3受体介导的疾病的方法。